Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
7 pending office actions • 3 art units • 6 examiners • 0 of 7 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
VIELA BIO, INC. currently manages 6 pending office actions in the Biotechnology & Pharmaceuticals technology area. These 6 actions are distributed among 5 distinct examiners, indicating that most matters are being reviewed by different individuals. However, the prosecution is relatively concentrated within the USPTO, as all 6 actions fall within only 2 distinct art units. CHUN WU DAHLE is the busiest examiner for the portfolio, holding 2 pending office actions.
The remaining pending office actions are handled by other distinct examiners. Having 6 pending actions across only 2 distinct art units suggests that the underlying technologies are closely related despite the variety of examiners. Practitioners can expect to interact with 5 distinct examiners, which may lead to varying prosecution timelines and outcomes. The role of CHUN WU DAHLE is central, as this examiner manages 2 of the 6 total pending actions, providing a point of consolidation in an otherwise distributed examiner pool within the Biotechnology & Pharmaceuticals technology area.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (14%) |
| Double-patenting + other | 2 (29%) |
| Multi-statute (no §101) | 4 (57%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DAHLE, CHUN WU | 2 | 50.2% | +51.2% |
| LANDSMAN, ROBERT S | 1 | 81.3% | +13.0% |
| WEN, SHARON X | 1 | 56.9% | +32.6% |
| SULLIVAN, DENNIS JOHN | 1 | 57.3% | +49.1% |
| WANG, CHANG YU | 1 | 33.5% | +53.5% |
| LEE, YIE CHIA | 1 | 69.2% | +46.6% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18615679 | CD40L-SPECIFIC TN3-DERIVED SCAFFOLDS FOR USE IN THE TREATMENT AND PREVENTION OF RHEUMATOID ARTHRITIS | LANDSMAN, ROBERT S | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18303303 | USE OF AN ANTI-CD19 ANTIBODY TO TREAT AUTOIMMUNE DISEASE | DAHLE, CHUN WU | 5d overdue |
| 18147287 | METHODS OF TREATING NEUROMYELITIS OPTICA SPECTRUM DISORDER | WANG, CHANG YU | 63d |
| 18559195 | USE OF AN ANTI-CD19 ANTIBODY TO TREAT MYASTHENIA GRAVIS | WEN, SHARON X | — |
| 17606306 | USE OF AN ANTI-CD19 ANTIBODY TO TREAT AUTOIMMUNE DISEASE | LEE, YIE CHIA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18303303 | USE OF AN ANTI-CD19 ANTIBODY TO TREAT AUTOIMMUNE DISEASE | DAHLE, CHUN WU | 5d overdue |
| 18147287 | METHODS OF TREATING NEUROMYELITIS OPTICA SPECTRUM DISORDER | WANG, CHANG YU | 63d |
| 18615679 | CD40L-SPECIFIC TN3-DERIVED SCAFFOLDS FOR USE IN THE TREATMENT AND PREVENTION OF RHEUMATOID ARTHRITIS | LANDSMAN, ROBERT S | — |
| 18415031 | HUMANIZED ANTI-CD19 ANTIBODIES AND THEIR USE IN TREATMENT OF ONCOLOGY, TRANSPLANTATION AND AUTOIMMUNE DISEASE | DAHLE, CHUN WU | — |
| 18559195 | USE OF AN ANTI-CD19 ANTIBODY TO TREAT MYASTHENIA GRAVIS | WEN, SHARON X | — |
| 18558505 | METHODS OF TREATMENT OF AUTOIMMUNE DISORDERS USING ILT7 BINDING PROTEINS | SULLIVAN, DENNIS JOHN | — |
| 17606306 | USE OF AN ANTI-CD19 ANTIBODY TO TREAT AUTOIMMUNE DISEASE | LEE, YIE CHIA | — |
| Art Unit | Apps |
|---|---|
| 1641 | 2 |
| 1642 | 2 |
| 1675 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18615679 | CD40L-SPECIFIC TN3-DERIVED SCAFFOLDS FOR USE IN THE TREATMENT AND PREVENTION OF RHEUMATOID ARTHRITIS | LANDSMAN, ROBERT S | — | §103§112DP | Non-Final OA | — | Pending | Mar 25, 2024 |
| 18415031 | HUMANIZED ANTI-CD19 ANTIBODIES AND THEIR USE IN TREATMENT OF ONCOLOGY, TRANSPLANTATION AND AUTOIMMUNE DISEASE | DAHLE, CHUN WU | — | §112Other | Non-Final OA | — | Pending | Jan 17, 2024 |
| 18559195 | USE OF AN ANTI-CD19 ANTIBODY TO TREAT MYASTHENIA GRAVIS | WEN, SHARON X | 1641 | §103§112 | Non-Final OA | — | Pending | Nov 06, 2023 |
| 18558505 | METHODS OF TREATMENT OF AUTOIMMUNE DISORDERS USING ILT7 BINDING PROTEINS | SULLIVAN, DENNIS JOHN | 1642 | §103§112DPOther | Non-Final OA | — | Pending | Nov 01, 2023 |
| 18303303 | USE OF AN ANTI-CD19 ANTIBODY TO TREAT AUTOIMMUNE DISEASE | DAHLE, CHUN WU | 1641 | §102§103§112 | Final Rejection | 5d overdue | Pending | Apr 19, 2023 |
| 18147287 | METHODS OF TREATING NEUROMYELITIS OPTICA SPECTRUM DISORDER | WANG, CHANG YU | 1675 | §103§112Other | Non-Final OA | 63d | Pending | Dec 28, 2022 |
| 17606306 | USE OF AN ANTI-CD19 ANTIBODY TO TREAT AUTOIMMUNE DISEASE | LEE, YIE CHIA | 1642 | §103§112Other | Non-Final OA | — | Pending | Oct 25, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial